We want to offer guidance and services that provide tools to ease completion of research in Denmark.
The aim is to create a joint infrastructure within the field of biobanks. Internationally, Denmark has a strong position in this field. The strong position is partly due to a long tradition of close collaboration between private companies and public hospitals in Denmark. Bio- and Genome Bank Denmark wants to contribute to strengthen the collaboration between hospitals and companies further and ensure that we have an even more targeted treatment of patients.
An area that is particularly of interest in the public-private collaboration is development of so-called “biomarkers”. Biomarkers can show whether a patient will benefit from a given medical treatment. Bio- and Genome Bank Denmark wants to assist researchers interested in biomarkers with required facilities.
Further readings (in Danish only):
- Paper of principles
- Organization chart
- Instructions for collaborations with companies (vejledning for samarbejde med virksomheder)
- Members of the Steering Committee
- Members of the Technical Advisory Board
- RBGB Annual Report 2018
- RBGB Annual Report 2017
- RBGB news letters
NATIONAL COLLABORATION BETWEEN BIOBANKS
In 2009, the Danish Cancer Biobank (DCB) was founded based on a report form The Danish Cancer Society from 2005.
The Danish Regions decided to establish the Danish Reuma Biobank (DRB) in 2014, and in 2015 the Pato Biobank that has existed since 1999 became a part of the structure. Subsequently, more biobanks have joined the infrastructure.
Today, Bio- and Genome Bank Denmark consists of:
- Danish Cancer Biobank (DCB)
- Danish Reuma Biobank (DRB)
- The Pato Biobank
- Danish Blood Donor Biobank (DBB)
- Danish Diabetes Biobank (DDB)
- Danish Genetic Biobank (DGB)
The biobanks are a national collaboration between (public) hospital departments.